ASCENTAGE (06855.HK): Lisaftoclax Enters 2026 Reimbursement List; Olverembatinib Renewed
NewTimeSpace News: On 16 November 2026, Ascentage Pharma Group International (stock code: 6855) published a voluntary announcement that two of its original Class 1 innovative drugs have been added to the 2026 edition of the National Reimbursement Drug List, which takes effect on 1 January 2027.
Lisaftoclax was included for the first time after negotiation, for adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma who have received at least one prior systemic therapy including a Bruton's tyrosine kinase inhibitor. Olverembatinib was renewed after renegotiation for adult patients with chronic myeloid leukaemia in chronic phase who are resistant or intolerant to first and second generation tyrosine kinase inhibitors, and for adult patients with the T315I mutation in chronic or accelerated phase.
Lisaftoclax is an in-house oral selective Bcl-2 inhibitor that restores normal apoptosis of cancer cells by selectively inhibiting the Bcl-2 protein. It was approved in China in July 2025 as the country's first domestically developed Bcl-2 inhibitor to reach the market. Olverembatinib is a novel oral third-generation BCR-ABL inhibitor supported by China's major new drug development programme. It was approved in China in November 2021 as the country's first third-generation BCR-ABL inhibitor, and the Company promotes it in China together with Innovent Biologics.
All approved indications of the Company's two innovative drugs are now covered by the national reimbursement list.
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output
- OSMUNDA: Closes RMB 100 Million Series D Led Exclusively by Lishui Green Valley Talent Osmunda New Fund
- INNOVENT BIO (01801.HK): Sintilimab Gets First CHMP Positive Opinion for First-Line NSCLC